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Abstract
We analyzed the gene expression patterns of 138 Non-Small Cell Lung Cancer (NSCLC) samples and developed a new
algorithm called Coverage Analysis with Fisher’s Exact Test (CAFET) to identify molecular pathways that are differentially
activated in squamous cell carcinoma (SCC) and adenocarcinoma (AC) subtypes. Analysis of the lung cancer samples
demonstrated hierarchical clustering according to the histological subtype and revealed a strong enrichment for the Wnt
signaling pathway components in the cluster consisting predominantly of SCC samples. The specific gene expression
pattern observed correlated with enhanced activation of the Wnt Planar Cell Polarity (PCP) pathway and inhibition of the
canonical Wnt signaling branch. Further real time RT-PCR follow-up with additional primary tumor samples and lung cancer
cell lines confirmed enrichment of Wnt/PCP pathway associated genes in the SCC subtype. Dysregulation of the canonical
Wnt pathway, characterized by increased levels of b-catenin and epigenetic silencing of negative regulators, has been
reported in adenocarcinoma of the lung. Our results suggest that SCC and AC utilize different branches of the Wnt pathway
during oncogenesis.
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Introduction
Lung cancer is the leading cause of cancer-related death in
both men and women throughout the world, and more than
fifteen thousand people in the United States die from the disease
each year [1]. About 80% of lung cancers are classified as non-
small cell lung carcinoma (NSCLC). Adenocarcinoma (AC) and
squamous cell carcinoma (SCC) are the two major subtypes of
NSCLC, each representing about 40% cases of NSCLC. SCC is
characterized as a poorly differentiated tumor subtype that
develops in the proximal airways and is strongly associated with
cigarette smoking. In contrast, AC usually arises in the peripheral
airways and is more commonly observed in non-smokers and
women.
High-throughput gene expression analysis has been widely used
to study cancer to facilitate the discovery of novel oncogenes and
elucidate the mechanism of tumorigenesis. These genome-wide
analyses usually result in the identification of hundreds or
thousands of genes with an altered expression pattern. However,
interpreting the relevance of these long gene lists remains a
significant challenge [2,3].
Several pathway analysis approaches have been developed to
uncover the molecular signaling patterns underlying these
candidate gene lists. One of the most common approaches is
based on statistical enrichment (e.g., hypergeometric distribution
with the Fisher’s Exact Test). These methods test the gene list of
interest for enrichment relative to groups of genes that are known
to share a common function. This approach, broadly referred to
here as functional group enrichment analysis (FGA), calculates the
statistical significance of the overlap with the goal of identifying
activated or repressed pathways. This basic method is used in
many major pathway analysis tools including Ingenuity, Database
for Annotation, Visualization and Integrated Discovery (DAVID),
and gene set enrichment analysis (GSEA) [4,5]. These tools have
been successfully applied to generate molecular insights in many
biological systems.
In this study, we analyzed a collection of 138 lung cancer
samples using an FGA approach with the goal of defining the
active pathways that differentiate the two major sample groups.
While developmental and cell cycle pathways were broadly
implicated, this approach was unable to identify specific molecular
pathways that were amenable to hypothesis testing. In an effort to
identify more precise pathways that were dysregulated in this data
set, we developed a new algorithm called Coverage Analysis with
Fisher’s Exact Test (CAFET). This algorithm specifically accounts
for the case where dysregulation of even a single pathway member
can result in altered pathway signaling. Using the CAFET
approach, we found that Wnt pathway components were
differentially expressed in SCC samples. Further characterization
of these samples revealed an inhibition of the canonical branch of
the Wnt pathway, coupled with an enhancement of the non-
canonical Wnt PCP signaling cascade. These results suggest that
lung SCC uses an alternate branch of the Wnt pathway for
survival and development.
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Gene expression data and analysis
Microarray gene expression data from 62 human lung AC and
76 lung SCC were downloaded from NCBI’s GEO (GSE8894).
Probe sets with a maximum intensity below 100 were removed.
Hierarchical clustering was performed with R using a Euclidean
distance metric and average linkage. The significance of
differential expression for each gene was evaluated using the two
primary clusters from the global clustering analysis. The false
discovery rate (FDR) was estimated using the Benjamini Hochberg
method [6]. Genes were defined as differentially expressed if at
least one probe had a FDR,0.05 and a mean difference greater
than 2.5-fold between the two groups (Tables S1 and S2).
Microarray data from a second lung cancer expression study
(GSE10245) comprised of 58 NSCLC samples (40 AC and 18
SCC) were also analyzed and processed in the same way as above.
Functional group enrichment analysis (FGA)
Functional gene sets were downloaded from two sources.
Human gene annotations were obtained from NCBI’s gene2go
table (June19, 2009 snapshot from ftp://ftp.ncbi.nih.gov/gene/
DATA/gene2go.gz), from which 10102 gene sets were extracted
with at least five genes above the maximum intensity threshold
in our data set. We also utilized the KEGG metabolic and
signaling pathways database, which contained 202 manually-
annotated human pathways with the same gene expression
threshold (June 19, 2009 snapshot from ftp://ftp.genome.jp/
pub/kegg/pathways).
In this study, we calculated FGA enrichment using Fisher’s
exact test and hypergeometric distribution. The p-value for the
enrichment of a gene set of NG genes and a functional group of NF
genes was calculated by:
p~
Xmin(NF,NG)
k~NC
NG
k
  
NT{NG
NF{k
  
NT
NF
   ð1Þ
Where NC is defined as the number of genes within the gene set
assigned to the functional group, NT is the total number of annotated
genes of microarray. The FGA approach is also illustrated
schematically in Figure 1. FDR was estimated using the Benja-
mini-Hochberg method, and a threshold of 0.05 was applied.
Coverage Analysis with Fisher’s Exact Test (CAFET)
CAFET calculates the degree to which samples with a desired
expression property were concentrated in a particular sample
cluster. In this study, the desired property for a single gene in a
single sample was its overexpression relative to the median
expression across all samples. Like the FGA, the CAFET metric is
based on the Fisher’s exact test and hypergeometric distribution.
However, instead of calculating the enrichment of genes as in
FGA, CAFET calculates the enrichment of samples with a certain
expression feature.
The p-value of CAFET for a single gene is calculated by:
p~
Xmin(SG,SP)
k~SC
SG
k
  
ST{SG
SP{k
  
ST
SP
   ð2Þ
where SG is the number of samples in the sample cluster of
interest, ST is the total number of samples, SP is the number of
samples with the expression pattern of interest, and SC is the
number of samples in SP that fall in SG. Our expression filtering
criterion focused on expression greater than 2.5-fold of the median
expression across of all samples, or on expression less than 0.5 fold
of the median. (Asymmetric thresholds were used because the
baseline noise limits the magnitude of down-regulation.) For any
gene with multiple probes, all those samples with at least one
probe reaching the criteria were taken into account. FDR was
again estimated using the Benjamini-Hochberg method, and a
threshold of 0.05 was applied.
A CAFET p-value and FDR can be calculated for a single gene
(as described above) or for an entire functional group. In the latter
case, the desired property is overexpression of any gene in the
functional group (illustrated schematically in Figure 1). For each
gene i=1 … n in a given functional group, SP(i) and SC(i) were
defined as the SC and SP in formula 2. We further defined SFP as
the union of samples sets for SP(i) for all gene i, i=1…n, and SFC
as the number of union of samples sets for SC(i) for all gene i,1…
n. The CAFET p-value of the functional group was then calculated
by:
p~
Xmin(SG,SFP)
k~SFC
SG
k
  
ST{SG
SFP{k
  
ST
SFP
   ð3Þ
FDR was then estimated as described previously. Only
functional groups with at least 5 genes with
P
SP(i)§5 were
considered.
Score of Wnt SCC signature
To assess the degree to which individual samples exhibited
dysregulation of the Wnt pathway, we developed an ad hoc
scoring function based on gene expression values. A normalized
expression value is calculated for each gene based on the average
intensity of all its probes after log2 transformation and
standardization. The score of the Wnt SCC signature for any
sample is the sum of expression values of upregulated genes
subtracting the sum of expression values of down-regulated genes.
Primary Tumor and Cancer Cell Line Samples
cDNA from 40 lung cancer samples (14 SCC and 26 non-SCC)
was obtained from Origene (Rockville, MD; product
#HLRT103). Expression of FZD6, DVL3, and WNT5A was
interrogated via RT-PCR according to the protocol below.
Total RNA from 12 primary human lung tumors and 12
matched normal tissue samples were obtained from Asterand
(Detroit, MI). Informed consent was obtained from patients by
Asterand under approval from the appropriate IRBs. The samples
were handled and maintained according to protocols approved by
the IRB of the Genomics Institute of the Novartis Research
Foundation (GNF).
SCC lung cancer cell lines LK2 (RIKEN, Japan), NCI-H520
(ATCC, Monassas, VA), LUDLU-1 (ECACC, UK) and HARA-1
(HSSRB, Japan) were maintained in HyClone RPMI-1640
medium supplemented with 10% FBS (Thermo Fisher Scientific
Inc., Waltham, MA). Non-SCC lung cancer cell lines ABC1
(HSSRB, Japan), PC14 (RIKEN, Japan), NCI-H2342, NCI-H209,
A549, NCI-H661, HCC827 and NCI-H522 (ATCC, Monassas,
VA) were maintained in the recommended media by their
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was used to extract total RNA from cancer cell lines.
Real-Time PCR Assays
For expression analysis, cDNA was prepared using the High
Capacity cDNA Archive Kit (Applied Biosystems, Foster City,
CA). All RT-PCR assays were performed in duplicate using pre-
designed gene-specific Taqman probes and Taqman Universal
PCR Master Mix (Applied Biosystems, Foster City, CA) on the
7900HT FAST Real-Time PCR System. Relative mRNA
expression of target genes was normalized to ACTB expression
as an internal amplification control.
Results
We analyzed gene expression data from 138 NSCLC samples,
classified into 76 SCC and 62 AC tumors [7]. Hierarchical
clustering separated the majority of the samples into two branches,
which we labeled as simply Group 1 and Group 2. Group 1was
primarily comprised of SCC samples (59 SCC, 4AC). Group 2 was
Figure 1. Schematic illustration of the FGA and CAFET approaches for pathway enrichment. Both the FGA and CAFET approaches begin
with the same data matrix of gene expression measurements, and both seek to assess the relevance of a particular Functional Gene Set (FGS) (i.e.,
pathway) in the division of samples into two groups. Red boxes indicate dysregulation of a specific gene in a specific sample. FGA approaches
employ a three-step process. In step 1, differentially expressed genes are identified, typically based on a t-test or ANOVA analysis. In step 2, genes
with a role the FGS of interest are identified. In step 3, Fisher’s exact test is used to test for enrichment of FGS genes among differentially-expressed
genes. CAFET employs a similar four-step process. In step 1, FGS genes are first identified and the corresponding sub-matrix is extracted. In step 2,
samples are evaluated for the presence of a particular gene expression signature. In this study, the signature is marked as present if one or more
pathway genes are dysregulated. In step 3, the division of samples between two groups of interest is defined. In step 4, Fisher’s exact test is used to
test for enrichment of samples containing the pathway signature among the sample group of interest. In cases where the majority of FGS members
are differentially regulated (A), both FGA and CAFET detect a statistically significant relationship between the FGS and the sample grouping.
However, in cases where each sample has only a few FGS members dysregulated (B), CAFET but not FGA results in a significant enrichment for the
associated FGS.
doi:10.1371/journal.pone.0025807.g001
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samples, and Group 2b, which contained the majority of the
remaining SCC samples that were not found in Group 1
(Figure 2). Recognizing that lung cancer is a very heterogeneous
disease even within histological classes, we specifically chose to use
the global, unsupervised clustering results as the basis for our
study. Specifically, we focused on identifying the molecular basis
distinguishing Group 1 from Group 2 lung cancer samples.
We identified 635 genes with significantly higher expression in
Group 1 (Table S1), and 740 genes with significantly higher
expression in Group 2 (Table S2). To identify relevant pathways
in these gene lists, we applied FGA analysis to these sets of genes.
We found that genes overexpressed in Group 1 were enriched in
functional groups related to cell cycle and development (Table
S3), while genes overexpressed in Group 2 had significant
association with many immune response functional groups (Table
S4).
Enrichment in functional groups related to cell cycle and
development was expected given their known roles in oncogenesis
and metastasis. However, the functional gene groups identified in
this analysis often contained hundreds or thousands of genes, and
as a result, the formulation of specific mechanistic hypotheses
proved difficult. Enrichment scores of more specific signaling
pathways using FGA were not statistically significant, and varying
filtering criteria for differential expression did not result in any
improvement.
We hypothesized that this lack of specificity was a fundamental
property of the enrichment analysis underlying FGA. Specifically,
the FGA approach is designed to detect pathways in which
multiple pathway genes are differentially expressed, and more
significant p-values are achieved when more pathway genes are
differentially expressed (Figure 1). The first step in FGA is the
identification of differentially expressed genes, typically involving a
statistical measure like a t-test or ANOVA. The second step
involves identifying the set of pathway genes for a pathway of
interest, and third step tests the enrichment of pathway genes
among differentially expressed genes. This procedure is quite
effective when the majority of pathway genes are differentially
expressed in each case sample studied (Figure 1A).
However, dysregulation of even a single pathway gene is often
sufficient to result in altered pathway signaling. Consider a study
in which all case samples have altered pathway activity, but where
each sample has a different pathway member dysregulated
(Figure 1B). In this case, FGA will not detect the importance of
the altered pathway.
To address this limitation, we developed a complementary
algorithm called Coverage Analysis with Fisher’s Exact Test
(CAFET). In the first step, data for pathway members are
extracted from the gene expression matrix. In the second key step,
CAFET identifies samples with a relevant gene expression
signature, which in our case can be defined by the dysregulation
of as few as one pathway member. The third step defines the
clinically relevant sample groups (e.g., case versus control, or SCC
versus AC). And the fourth step tests the enrichment of
dysregulated samples among the sample groups using the same
Fisher’s exact test as in FGA (Figure 1). The CAFET procedure is
sensitive to data sets in which the majority of pathway members
are dysregulated (Figure 1A), as well less obvious cases in which
only one or a few pathway members are dysregulated (Figure 1B).
In contrast to FGA where more significant p-values are achieved
when more pathway genes are differentially expressed, CAFET
reports more significant p-values when more samples have at least
one differentially expressed pathway member.
We used CAFET to identify functional groups which signifi-
cantly differentiated Group 1 from Group 2. Consistent with the
FGA analysis, Group 1 samples showed significant CAFET
enrichment for many developmental process related functional
groups (Table 1; full results in Tables S5 and S6). As designed,
this list also included specific enriched molecular pathways. The
Wnt receptor activity pathway (GO:0042813) was among the most
enriched functional groups (p=8.55E213, FDR=7.94E211),
with ninety lung cancer samples expressing at least one of the
following seven components (FZD3; FZD4; FZD6; FZD7; FZD8;
FZD10; RYK) at least 2.5-fold above the average of Group 2
samples. Sixty of these ninety samples were found to cluster with
Group 1, indicating a strong association of the Wnt pathway.
Given the known roles for Wnt signaling in oncogenesis and
metastasis, we focused our study on the Wnt pathway to further
investigate its potential dysregulation in the two main NSCLC
subtypes [8,9].
We first expanded our list of Wnt pathway members to 172
genes in nine Wnt-related functional groups (Tables S7 and S8),
and then applied CAFET on a gene-by-gene basis, testing whether
samples with substantially altered expression were enriched among
the SCC-dominated Group 1. This approach identified 53 genes
that displayed differential expression and could be associated
specifically with the Group 1 cluster (Table 2). Of these 53 genes,
34 were observed to be strongly up-regulated in Group 1, while 19
displayed significantly reduced expression levels. According to the
CAFET method, SOX2 was the most significantly enriched gene in
the SCC cluster (FDR=3.86E218), with eighty eight percent of
samples with high SOX2 expression (54 of 61) clustering to Group
1. SOX2 has recently been identified as a lineage survival oncogene
in lung and esophageal squamous carcinoma [10–12].
Figure 2. Hierarchical clustering of 138 NSCLC samples reveals two predominant sample clusters. Hierarchical clustering was performed
based on log-transformed expression data using Euclidean distance and average linkage. The brown branches of the tree were labeled ‘‘Group 1’’,
and the light blue cluster was labeled ‘‘Group 2’’. Group 2 was further subdivided into Group 2a (dark blue) and Group 2b (red).
doi:10.1371/journal.pone.0025807.g002
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of altered expression seemed to indicate an up-regulation of the
non-canonical Wnt/PCP pathway and down-regulation of the
canonical Wnt/b-catenin signaling branch in Group 1 samples
(Figure 3 and Table 2). Several of these findings are summarized
here:
- Four genes (RYK, CELSR2, VANGL1, VANGL2) described as
upstream, positive regulators of the Wnt/PCP pathway [13] were
all enriched by CAFET in Group 1 samples.
- Two Wnt ligands, WNT5A and WNT11 [14], were also found
overexpressed in Group 1 samples. Both of these Wnt ligands are
known to enhance the non-canonical branch of the Wnt pathway
while inhibiting the canonical signaling cascade. Of the 38 samples
overexpressing WNT5A, 37 were found in Group 1. Similarly all
nine samples overexpressing WNT11 were Group 1 samples.
- The Frizzled receptor FZD6 was exclusively overexpressed
among Group 1 samples. This gene was reported to repress
canonical Wnt signaling [14,15] and to activate the non-canonical
Wnt pathway [14].
- Samples overexpressing two LRP6 inhibitors, SOSTC1 and
KREMEN1, were enriched among Group 1 samples. The LRP6
co-receptor is required for canonical Wnt signaling, but not non-
canonical signaling [16,17].
- DIXDC1 was down-regulated in 21 samples, 16 of which were
in Group 1. This gene functions as a switch by enhancing
canonical Wnt signaling while inhibiting non-canonical Wnt
signaling [18,19].
- Upregulation of SENP2, accompanied by reduced expression
of ILK in Group 1, indicated a potential increase in b-catenin
degradation and inhibition of the canonical signaling cascade
[18,19].
Among all the changes in the Wnt pathway, there were only
three changes that specifically indicated a potential activation in
canonical signaling: increased expression of WNT2B, and the
down-regulation of FRZB and SKP1 [20,21]. In contrast, 12 of the
observed changes were consistent with the activation of the non-
canonical Wnt pathway or inhibition of the canonical signaling
branch. Interestingly, we also saw a decrease expression of
Table 1. Most significant functional groups identified by CAFET based on genes overexpressed in Group 1 samples.
FG_ID FG_Name
Gene
No.
a
Total
No.(138)
b
G1
No. (63)
c G1_pValue G1 FDR
GO:0030299 intestinal cholesterol absorption 5 79 60 2.08E218 1.02E215
hsa03030 DNA replication - Homo sapiens (human) 33 87 62 1.58E217 5.08E215
GO:0001840 neural plate development 5 70 55 3.93E216 9.87E214
GO:0000777 condensed chromosome kinetochore 40 92 62 4.92E215 8.75E213
GO:0005663 DNA replication factor C complex 6 57 48 5.43E215 9.48E213
GO:0048854 brain morphogenesis 7 77 57 6.03E215 1.02E212
GO:0033170 protein-DNA loading ATPase activity 5 56 47 2.35E214 3.37E212
GO:0003689 DNA clamp loader activity 5 56 47 2.35E214 3.37E212
GO:0006297 nucleotide-excision repair, DNA gap filling 17 81 58 2.95E214 4.10E212
GO:0048048 embryonic eye morphogenesis 7 76 56 3.98E214 5.47E212
GO:0035058 sensory cilium assembly 5 59 48 1.13E213 1.39E211
GO:0000779 condensed chromosome, centromeric region 43 95 62 1.17E213 1.40E211
GO:0007618 mating 5 80 57 2.06E213 2.44E211
GO:0051588 regulation of neurotransmitter transport 5 92 61 2.24E213 2.60E211
GO:0046928 regulation of neurotransmitter secretion 5 92 61 2.24E213 2.60E211
GO:0030057 desmosome 19 101 63 6.46E213 6.17E211
hsa03430 Mismatch repair - Homo sapiens (human) 21 84 58 8.22E213 7.77E211
GO:0006596 polyamine biosynthetic process 5 49 42 8.37E213 7.84E211
GO:0042813 Wnt receptor activity 7 90 60 8.55E213 7.94E211
GO:0005657 replication fork 28 97 62 8.74E213 7.97E211
GO:0002347 response to tumor cell 5 97 62 8.74E213 7.97E211
GO:0070567 cytidylyltransferase activity 6 52 43 5.09E212 3.98E210
GO:0005871 kinesin complex 12 73 53 5.85E212 4.47E210
GO:0031507 heterochromatin formation 5 73 53 5.85E212 4.47E210
GO:0008088 axon cargo transport 10 92 60 6.36E212 4.78E210
GO:0042490 mechanoreceptor differentiation 9 92 60 6.36E212 4.78E210
GO:0042491 auditory receptor cell differentiation 6 71 52 8.50E212 6.30E210
GO:0050892 intestinal absorption 8 96 61 1.19E211 8.76E210
a: number of genes in the functional group with at least one overexpressed sample.
b: the total number of samples overexpressing at least one gene in the functional group (out of 138 samples total).
c: the number of Group 1 samples overexpressing at least one gene in the functional group (out of 63 samples in Group 1).
doi:10.1371/journal.pone.0025807.t001
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pathway [22].
These results support the model of increased Wnt/PCP
signaling and decreased canonical Wnt signaling in Group 1
SCC samples (Figure 4). To test the generality of these findings,
we examined the role of the Wnt pathway in multiple independent
data sets. First, we tested whether the Wnt/PCP signature could
be validated in a second, independent gene expression data set
[23] and scored the 58 NSCLC samples (40 ACC and 18 SCC)
according to the differential expression of genes listed in Table 2.
Samples with high Wnt/PCP scores were strongly enriched for
SCC subtype (Figure 5A), confirming a general association
between SCC and Wnt/PCP signaling in primary lung tumor
sample datasets.
Next, we performed quantitative PCR on three Wnt pathway
genes (FZD6, DVL3, WNT5A) in a commercial panel of 40 lung
cancer samples (Origene; Rockville, MD). Although the overex-
pression of DVL3 did not achieve statistical significance (p=0.057),
FZD6 and WNT5A were both significantly overexpressed in SCC
samples relative to the non-SCC samples (p=0.00056 and
p=0.0011, respectively) (Figure 5B).
In a third validation set, we examined a set of freshly obtained
primary lung SCC and AC samples (Asterand; Detroit, MI). We
probed the expression of nine representative genes of the Wnt/
Table 2. Genes in the Wnt pathway with significant CAFET enrichment.
Up-regulation Down-regulation
Gene Total No
a G1 No
b G1_FDR Gene Total No
c G1 No
d G1_FDR
SOX2 61 54 3.86E218 TLE2 39 33 2.94E207
FZD10 60 53 1.67E217 FZD5 35 28 6.08E205
VANGL2 42 41 1.98E215 CTBP1 21 19 0.000138
FZD7 46 42 4.62E213 MAPK9 23 19 0.001634
PRKX 37 36 8.23E213 ILK 11 11 0.001858
PRKY 39 37 2.82E212 CAMK2D 51 34 0.002322
CELSR2 41 38 7.28E212 FRZB 32 24 0.002315
WNT5A 38 36 8.82E212 PRKCA 35 25 0.005208
TBL1XR1 35 33 2.49E210 PPAP2B 37 26 0.00568
DVL3 27 27 8.30E210 CCND1 39 27 0.00611
SLC9A3R1 30 29 1.69E209 FZD8 27 20 0.010784
TBL1X 42 35 1.10E207 SFRP4 52 33 0.011249
WNT2B 21 21 3.05E207 PRKCB 35 24 0.016357
SOSTDC1 46 36 1.48E206 CCND3 19 15 0.018143
SENP2 26 24 1.69E206 MMP7 43 28 0.018448
CSNK2A1 20 19 1.98E205 TGFB1I1 23 17 0.027185
RYK 20 19 1.98E205 PPP3CA 18 14 0.031241
FZD6 16 16 2.66E205 SKP1 33 22 0.042493
MYC 25 21 0.000348 DIXDC1 22 16 0.044592
SMAD3 29 23 0.000702
FOSL1 44 31 0.001016
KREMEN1 24 19 0.003803
HHEX 26 20 0.00483
TP53 9 9 0.007524
WNT11 9 9 0.007524
PLCB4 34 24 0.008865
SMAD2 12 11 0.009335
TLE1 17 14 0.013585
DVL2 8 8 0.015954
RNF138 11 10 0.018424
VANGL1 11 10 0.018424
BARX1 21 16 0.02324
LEF1 16 13 0.024639
LDB1 10 9 0.035772
a: number of samples with high expression.
b: number of Group 1 samples with high expression.
c: number of samples with low expression.
d: number of Group 1 samples with low expression.
doi:10.1371/journal.pone.0025807.t002
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FZD6, FZD7 and FZD10) using real time RT-PCR (Figure 5C).
With the exception of FZD5, we observed significantly increased
expression of the Wnt/PCP components in SCC tumors relative to
their matched controls, and also relative to the AC samples.
To determine if the observed WNT/PCP pathway enrichment
would translate from in vivo primary samples to in vitro SCC cell
line models, we examined expression of eight differentially
expressed genes in four SCC lung cancer cell lines: HARA-1,
LK2, NCI-H520 and LUDLU-1. Expression of five of the eight
genes (WNT5A, RYK, DVL3, FZD6, and FZD10) was significantly
up-regulated in the four SCC cell line samples relative to the eight
non-SCC NSCLC controls (Figure S1). These cell lines may offer
convenient tools to further investigate the role of the Wnt/PCP
signature in SCC, as well as provide models for validation of select
Wnt/PCP genes as potential therapeutic targets for SCC
progression and metastasis.
Discussion
Pathway analysis algorithms are aimed at calculating the
statistical significance of gene expression changes in order to
identify known biological pathways most affected by the observed
changes. FGA implicitly assumes that a majority of genes in a
pathway need to be overexpressed to activate the pathway.
However, dysregulation of one or two genes is often enough to
significantly alter cell signaling, and we developed the CAFET
algorithm based on this underlying assumption.
By comparison to more well-known FGA enrichment methods,
the CAFET approach offers complementary strengths and
weaknesses. The statistical power of Fisher’s exact test is highly
dependent on the total number of observations being compared.
Since FGA tests enrichment along a gene axis, it is most
appropriate when the number of genes in a pathway is large but
can tolerate a relatively small number of samples. In contrast,
CAFET performs enrichment along the sample axis, so statistical
power is most dependent on the number of samples being studied.
CAFET therefore would not be appropriate when the samples
sizes are small. However, when samples sizes are large as in the
lung cancer data set examined here, CAFET can accurately
interrogate gene sets with relatively few genes that are typically
characteristic of specific molecular pathways. Based on these
characteristics, it is not surprising that CAFET identified the role
of the Wnt pathway in our study while FGA did not. Like other
variants of gene set enrichment analysis [24,25], we believe the
CAFET approach will be broadly applicable to pathway
enrichment analysis in other large data sets as well.
Many previous studies have explored genomic differences in
lung cancer subclasses based on histological distinctions, including
differences between AC and SCC (for example [26,27]). However,
Figure 3. Mapping gene expression changes on the Wnt pathway revealed strong upregulation of PCP signaling and
downregulation of canonical signaling. The three branches of Wnt signaling are shown –calcium (pink background), beta-catenin (green
background), and PCP (blue background). Up/down arrows indicate overexpression and downregulation, respectively, in Group 1 samples. Genes
whose expression change is consistent with canonical pathway inhibition and PCP pathway activation are colored red. Those genes promoting
canonical signaling and inhibiting the PCP branch are colored green. Genes with no significant change in expression, or whose expression change has
no selectivity between the canonical and non-canonical branches are colored white. The down-regulation of CAMK2D and PRKCA (dark blue) acts to
inhibit Wnt Ca2+ signaling.
doi:10.1371/journal.pone.0025807.g003
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PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e25807in this study, we instead chose to use the results of global,
hierarchical clustering of gene expression data to define the
comparison groups, effectively stratifying samples based on a
molecular rather than histological profile. This approach split the
SCC samples into two subclasses, one of which showed greater
molecular similarity to AC.
The division of samples based on global hierarchical clustering
led to the initial identification by CAFET of the Wnt pathway’s
importance in lung cancer. Although CAFET also detected the
Wnt pathway as being statistically enriched when simply
comparing SCC to AC (data not shown), the subset of SCC in
Group 2b was clearly more similar to the AC samples in Group 2a
than the remaining SCC samples in Group 1.
Previous reports using gene expression profiling have also noted
genomic similarities between AC and certain subsets of SCC
[28,29]. Interestingly, Wilkerson et al. previously characterized a
‘‘secretory’’ subclass of SCC which overexpressed thyroid
transcription factor 1 (NKX2-1/TTF1), the corresponding protein
of which is also highly expressed in AC [30]. In the current study,
NKX2-1/TTF1 also showed significantly higher expression in
Group 2 relative to Group 1 samples (p=1.55E231), as well as
significantly higher expression in Group 2b relative to Group 1
(p=1.12E210). These results reinforce the value of studying
differences between groups based on genomic profiling rather than
histological classification.
Having used the CAFET method to identify a strong
enrichment of the Wnt pathway components in NSCLC, we then
pursued more detailed characterization. Specifically, we observed
a selective up-regulation of the Wnt/PCP pathway, accompanied
by potential silencing of the canonical Wnt signaling branch in the
SCC subtype. Although the CAFET approach is only applicable
in large data sets with many cancer samples, these results
demonstrate that CAFET is a powerful and complementary tool
for pathway analysis.
The Wnt pathway is highly evolutionarily conserved. Its
signaling is initiated by the binding of an extracellular Wnt ligand
to a Frizzled-family receptor at the cell surface. Dependent on the
specific combination of Wnt/Frizzled isoforms and the presence of
specific downstream components, this binding event can signal
through three different intracellular branches: the canonical Wnt
pathway which terminates in b-catenin-mediated transcription,
the Wnt calcium pathway which results in calcium-dependent
signaling, and Wnt planar-cell-polarity (PCP) pathway which
modulates cytoskeletal dynamics. The latter two are also referred
to as non-canonical Wnt pathways [31].
The function of Wnt signaling in healthy adult lung is unclear,
however it is hypothesized to play a role in the maintenance of the
stem cell niche in the proximal and distal airways [32,33]. In
addition, several groups have linked hyperactivation of Wnt
signaling to oncogenesis and metastasis, through dysregulation of
such cell processes as cell proliferation, self-renewal capacity,
differentiation and cell movement [8,9].
The canonical branch of the Wnt pathway is by far the most
thoroughly studied [8], and has been demonstrated to play a
critical role in a wide range of cancers. In colorectal cancer,
mutations of b-catenin, APC, and Axin increase the stability of b-
catenin, leading to the overexpression of downstream targets and
promoting cell proliferation and regulate cell differentiation [9].
Dysregulation of canonical Wnt signaling has also been
demonstrated in lung cancer, mediated through epigenetic
silencing of negative regulators such as SFRP1 and WIF-1
[34,35] or rare mutations in APC and b-catenin [36,37]. In
addition, exposure to cigarette smoke activates the canonical Wnt
pathway in human bronchial epithelial cells and induces a tumor-
like phenotype [38]. Hyperactivation of the canonical Wnt
pathway was also observed in metastatic AC subpopulations and
demonstrated to be important for AC metastasis to brain and
bone [39].
Figure 4. Differential expression pattern of Wnt signature genes in lung cancer samples. Each column represents one of the 138 lung
cancer samples as ordered in Fig 1. SCC samples are colored brown and AC samples are colored blue. Each row represents a Wnt pathway gene in
Table 2, ranked according to p-value. Red and blue cells indicate overexpression and down-regulation, respectively, of individual genes in specific
samples.
doi:10.1371/journal.pone.0025807.g004
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PCP branch, have been much less studied. Signal transduction
from the Wnt/Frizzled/Dsh complex proceeds through unique
protein components, including VANGL, PRICKLE, CELSR [40].
This signaling activates the Rho GTPases Rac, Cdc42, and RhoA,
which in turn modulate cytoskeleton structure and gene
transcription. The Wnt/PCP pathway regulates planar cell
polarity as well as the coordinated cell movement in embryos
during gastrulation [41]. The Wnt/Frizzled/Dsh complex also
stimulates the Wnt calcium pathway by increasing intracellular
calcium and activating two calcium dependent kinases, calmod-
ulin-dependent protein kinase II (CAMKII) and protein kinase C
(PKC) [42].
To our knowledge, this is the first observation of the selective
enhancement of the Wnt/PCP pathway and inhibition of the
canonical Wnt pathway in lung SCC. Although the direct
evidence of Wnt/PCP pathway in cancer development is sparse,
its potential involvement in tumor progression, angiogenesis,
invasion and metastasis has been the focus of recent research.
Several groups have identified WNT5A as a key regulator of
metastasis in melanoma, breast and gastric cancers. In addition
both FZD7 and FZD10 have been shown to regulate migration
and metastasis of gastric, colorectal and synovial carcinomas via
the non-canonical Wnt signaling cascade [42,43]. Furthermore,
inhibition of VANGL1, an essential component of Wnt/PCP
pathway that is overexpressed in SCC, was found to inhibit the
size and metastatic potential of gastric tumors in mice [44]. Due to
its role in regulating cell adhesion and cell migration in response to
microenvironmental cues, it is not surprising the Wnt/PCP
pathway is emerging as a central player in tumor invasion and
metastasis [42,43].
Interestingly, the SCC samples in Group 2b do not share the
Wnt/PCP pathway signature (Figure 4), and every validation
data set examined also contained a small number of SCC samples
without activation of Wnt/PCP signaling. We are unable to find
any secondary correlates that associate with this SCC subclass.
The clinical relevance of this subset of SCC samples that lack the
Wnt/PCP pathway signature is still an open question, but these
findings suggest a potential avenue of study for patient
stratification.
Until recently, SCC and AC were treated with a very similar
clinical approach [45]. In this study, we present a clear molecular
pathway that is highly associated with these two subtypes of. Our
analysis indicates that the Wnt/PCP expression is significantly
different between a subgroup of SCC and AC. We believe that
these results provide important insights on the mechanisms of
SCC formation. Moreover, we suggest that targeting individual
components of this pathway may also be of therapeutic interest.
Supporting Information
Table S1 Genes overexpressed in Group 1 samples compared to
Group 2 samples.
(XLSX)
Figure 5. Confirmation of Wnt/PCP signature in SCC of lung. A) Activation of Wnt/PCP signaling in SCC of lung was confirmed in a second
independent expression data set. Samples from an additional lung cancer data set [23] were also evaluated for Wnt/PCP signaling using the same
scoring system applied to the initial data set. Results showed a strong enrichment of SCC among high-scoring samples. B) Quantitative PCR was also
done on three Wnt pathway genes (FZD6, DVL3, WNT5A) in 40 commercially-obtained lung cancer samples. The expression of WNT5A and FZD6were
significantly higher in SCC samples. C) RT-PCR confirmed overexpression of Wnt pathway components in SCC of lung. The expression of nine genes in
the Wnt pathway was measured in 12 SCC and 12 non-SCC lung samples. All expression measurements were relative to matched normal lung
samples. These data showed consistent upregulation in SCC relative to non-SCC samples. Actin was used as a control for normalization.
doi:10.1371/journal.pone.0025807.g005
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Group 1 samples.
(XLSX)
Table S3 Functional groups enriched by FGA analysis among
genes overexpressed in Group 1 samples.
(XLSX)
Table S4 Functional groups enriched by FGA analysis among
genes overexpressed in Group 2 samples.
(XLSX)
Table S5 Functional groups enriched by CAFET analysis
among genes overexpressed in Group 1 samples.
(XLSX)
Table S6 Functional groups enriched by CAFET analysis
among genes overexpressed in Group 2 samples.
(XLSX)
Table S7 Functional groups related to the Wnt pathway.
(XLSX)
Table S8 Genes related to the Wnt pathway.
(XLSX)
Figure S1 Expression of Wnt pathway genes in SCC cell lines
relative to non-SCC controls. Five of the eight genes examined
had significantly higher expression (and lower delta(Ct) values) in
SCC samples (p,0.01).
(TIF)
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